Entries Written By Team angelMD
If you’ve been around AngelMD for any length of time, you’ve heard us talking about investing in what you know. It’s the key that makes AngelMD investment so strong.
In this episode, AngelMD CEO Tobin Arthur discusses the topic, and helps to define the ways to use your own knowledge to make investment decisions.
The following companies all joined AngelMD in May of 2019. Follow the companies of your choice to stay up to date with their progress and activity.
- Rethink Technologies
- Green Earth Clean Hands Alliance
- MAG Optics
- Biointeractive Technologies
In this week’s episode, Tobin and Jeff discuss the methods that they use to continually increase their financial literacy. Make sure to check out the show notes below to find links to resources mentioned in the podcast.
- Intelligent Investor – Benjamin Graham
- One Up On Wall Street – Peter Lynch
- The Most Important Thing – Howard Marks
- Wall Street Journal
- BarronsSeeking Alpha
- Good to Great – Jim Collins
- Jeff Bezos (Amazon)
- The Investors Podcast “We Study Billionairs”
- How I Built This – Guy Roz
- Motley Fool
- Stansberry Investor Hour – Dan Ferris
- Trailing Stops
- The Greatest Trade Ever
- Turning the Flywheel
Each of the following companies joined AngelMD during the month of April, 2019. Make sure to follow the companies that are operating within your areas of interest in order to stay up to date with their progress.
Congratulations are in order for AngelMD portfolio company Artoss, Inc. Artoss is a medical device company that has developed NanoBone, an advanced synthetic bone graft technology.
NanoBone was tested alone (without addition of autograft or bone marrow aspirate) in the ASTM International standardized animal model and found to be equivalent to the “gold standard” autograft in fusion rate.
James J. Cassidy, Ph.D., Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, said, “The ASTM standard animal model for lumbar intertransverse process spinal fusion is a very challenging model designed to replicate clinically relevant fusion rates for iliac crest autograft in the posterolateral spine.
A majority of bone void fillers must be mixed with autograft in order to achieve equivalent fusion rates to autograft alone. We’re pleased to offer surgeons a synthetic alternative to autograft that does not require mixing with autograft or bone marrow. Using a synthetic bone void filler alone offers significant cost savings to hospitals. NanoBone stands alone.”
“NanoBone Bone Graft used as a standalone in posterolateral spinal fusion represents asignificant advancement in patient care.” said J. Eric Gee, M.D. “Eliminating the need to mix synthetic graft with autograft or to harvest and concentrate bone marrow aspirate will save time and money as well as streamline operating room procedures.”
NanoBone Bone Graft products have been used in Europe and the US for more than ten years in more than 100,000 clinical cases across all indications. They have been available in the United States through Artoss, Inc. since 2015.